30 recruiting, 24 unknown, 12 not yet recruiting, 8 completed. 88 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 88 | Recruiting 30, Unknown 24, Not yet recruiting 12, Completed 8, Terminated 6, Active not recruiting 3, Withdrawn 3, Suspended 2 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) Iberdomide, CAR-T Leukapheresis, CAR-T Infusion - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Shambavi Richard | 22 | 2026-07-01 | 2026-07-27 |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma RN9101 injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 19 | 2026-07-01 | 2026-06-10 |
| Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Chimeric Antigen Receptor T Cells (CAR-T) - Relapsed/Refractory Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Chulalongkorn University | 3 | 2026-06-01 | 2026-03-09 |
| A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. QI-019B Injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-04-15 | 2026-04-20 |
| A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma IMV102 treatment - Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-04-14 | 2026-09-03 |
| A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. QI-019A Injection - Multiple Myeloma (MM) | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-03-03 | 2026-07-22 |
| IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma IASO104 - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-02-15 | 2026-01-20 |
| SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma SL4903 Autologous T-Cell Injection - Relapsed and Refractory Multiple Myeloma (RRMM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-02-01 | 2026-02-10 |
| JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma JY232 Injection - Multiple Myeloma | Early Phase 1 | Recruiting | Shenzhen Genocury Biotech Co., Ltd. | 9 | 2026-01-20 | 2026-01-13 |
| A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） LVIVO-TaVec400 product - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 38 | 2026-01-10 | 2026-02-10 |
| IASO206 in Patients With Relapsed/Refractory Multiple Myeloma IASO206 injection - Relapsed/Refractory Multiple Myeloma (RRMM) | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-01-08 | 2026-10-27 |
| A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma LVIVO-TaVec200 product - Multiple Myeloma | Early Phase 1 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 36 | 2025-12-10 | 2025-12-19 |
| A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma QLS32015 - Relapsed/Refractory Multiple Myeloma (RRMM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-09-15 | 2025-09-22 |
| An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies OriV508 Injection - Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 40 | 2025-09-08 | 2026-07-21 |
| A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 24 | 2025-07-23 | 2025-10-01 |
| Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma Single dose injection of certain dose of UWD-00B, MMF Immunosuppression - Multiple Myleoma, Refractory and Relapsed Multiple Myeloma | Early Phase 1 | Suspended | Wondercel Biotech (ShenZhen) | 30 | 2025-07-01 | 2026-05-07 |
| A Study of CT0596 in Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Plasma Cell Leukemia | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2025-06-25 | 2025-08-01 |
| Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research Metabolically Armed BCMA CAR-T cells. - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 36 | 2025-06-23 | 2025-07-25 |
| A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors RN1101 injection - B Cell Lymphoma, Multiple Myeloma | Early Phase 1 | Recruiting | YANRU WANG | 21 | 2025-05-06 | 2025-07-10 |
| A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma 18F-FDG, 68Ga-BC1 - Multiple Myeloma and Malignant Plasma Cell Neoplasms | Early Phase 1 | Recruiting | Peking University First Hospital | 50 | 2025-04-15 | 2025-06-06 |
Showing 20 of 88. Sign in to see all of them.
Recurrence (10) · Lymphoma, Non-Hodgkin (8) · Leukemia, Plasma Cell (6) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Neoplasms, Plasma Cell (3) · Burkitt Lymphoma (2) · Fasting (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Immunoglobulin Light-chain Amyloidosis (2) · Leukemia (2)
Hematologic Diseases (88) · Hemic and Lymphatic Diseases (88) · Immune System Diseases (88) · Immunoproliferative Disorders (88) · Neoplasms (88) · Neoplasms by Histologic Type (88) · Blood Protein Disorders (87) · Cardiovascular Diseases (87) · Hemorrhagic Disorders (87) · Hemostatic Disorders (87) · Lymphoproliferative Disorders (87) · Paraproteinemias (87) · Vascular Diseases (87) · Neoplasms, Plasma Cell (85) · Pathological Conditions, Signs and Symptoms (16)
Cyclophosphamide (6) · Dexamethasone (5) · 68Ga-pentixafor (4) · Bortezomib (4) · fludarabine (4) · Granulocyte Colony-Stimulating Factor (3) · Lenalidomide (3) · Melphalan (3) · Filgrastim (2) · Fluorodeoxyglucose F18 (2) · Immunotherapy, Adoptive (2) · Positron Emission Tomography Computed Tomography (2) · iberdomide (2) · 13-valent pneumococcal vaccine (1) · Acetaminophen (1)
Institute of Hematology & Blood Diseases Hospital, China (8) · Zhejiang University (7) · Shanghai Changzheng Hospital (6) · Washington University School of Medicine (6) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · Hrain Biotechnology Co., Ltd. (3) · Abramson Cancer Center at Penn Medicine (2) · Hebei Senlang Biotechnology Inc., Ltd. (2) · Peking Union Medical College Hospital (2) · Peking University First Hospital (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Rutgers, The State University of New Jersey (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Xinqiao Hospital of Chongqing (2)
China (56) · United States (22) · Denmark (1) · Italy (1) · Sweden (1) · Thailand (1)
Farrokh Dehdashti, M.D. (2) · John F DiPersio, M.D., Ph.D. (2) · Juan Du, Doctor (2) · Alfred Garfall, MD (1) · Amanda Cashen, M.D. (1) · Amany Keruakous, MD (1) · Amany RA Keruakous, MD (1) · Anton Nosov, MD (1) · Carol A Huff, MD (1) · Cesar Rodriguez (1) · Cesar Rodriguez, MD (1) · Christian B Gocke, MD, PhD (1) · Chunrui Li (1) · Dan Vogl, MD (1)
PMID 37192741, PMID 39501801, PMID 40540129, PMID 31776631, PMID 32826320, PMID 32989091, PMID 33626253, PMID 34651291, PMID 34677626, PMID 35177672, PMID 35468680, PMID 36725117, PMID 36762851, PMID 37093350, PMID 37272512, PMID 37735756, PMID 38230766, PMID 38703748, PMID 41062204, PMID 41882404, PMID 41925575, PMID 42378054, PMID 42839103
P30CA072720 (2), P01CA015396 (1), P30CA006973 (1), P30CA012197 (1), R42CA257797 (1)